Circulating tumor DNA as a biomarker in perihilar cholangiocarcinoma: a feasibility study

Circulating tumor DNA as a biomarker in perihilar cholangiocarcinoma: a feasibility study - circulating tumor DNA in perihilar cholangiocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43203

Enrollment

Registered

2016-08-17

Start date

2016-09-29

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary tract cancer perihilar cholangiocarcinoma

Interventions

Biomarker

ctDNA

Perihilar Cholangiocarcinoma

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: -Patients older than 18 years -Undergoing explorative laparotomy, diagnostic laparoscopy or percutaneous biopsy -Able to understand the information given and provide written informed consent

Exclusion criteria

Exclusion criteria: -18 years or younger -Unfit for laparotomy/ diagnostic laparoscopy/ biopsies or blood analyses in palliative chemotherapy studies -HIV/AIDS/hepatitis C in medical history -Not able to give informed consent (language, intellectual capacities, etc.)

Design outcomes

Primary

Measure	Time frame
-To determine if ctDNA is presentcan be reliably detected in patients with PHC. -If ctDNA is presentdetected, we will assess if the mutational profile of the tumor matches the profile of the ctDNA	—

Secondary

Measure	Time frame
-To perform a hotspot mutation analysis in patients with pathologically proven PHC	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)